MiMedx Group on the Street: Analyst Recommendations in January
MiMedx Group (MDXG) operates in the regenerative biomaterials segment. MiMedx is a leading global supplier of amniotic tissue products and has supplied over a million allografts in wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. Of the four analysts covering MiMedx Group in January 2018, three have given the stock a “buy” rating, and one analyst has given it a “strong buy” rating.